Home > News > Clinical Trial of VivaGel for Genital Herpes
June 26th, 2006
Clinical Trial of VivaGel for Genital Herpes
Abstract:
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) today announced the submission of a second Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for a clinical trial of VivaGel™ (SPL7013 Gel). The clinical trial is in support of the product’s second clinical indication, prevention of genital herpes.
Source:
pipelinereview.com
Bookmark:
| Related Links |
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||